TachyarrhythmiaNCT04025710
Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)
A study testing BIOMONITOR III and BIOMONITOR IIIm in people with Tachyarrhythmia and Atrial Fibrillation (AF), run by Biotronik SE & Co. KG at 27 sites in 6 countries.
Trial summary
This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III and BIOMONITOR IIIm that are discovered or remain even after risk analysis, risk mitigation and successful conformity assessment. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Tachyarrhythmia, Atrial Fibrillation (AF), Syncope
- What is being tested?
- BIOMONITOR III and BIOMONITOR IIIm
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 167 participants
- Where
- 27 sitesin 6 countries
- Study dates
- 17 Oct 2019to 6 Apr 2022
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient is at high risk of developing a clinically important cardiac arrhythmia; or
- Patient is undergoing investigation for symptoms such as palpitations, pre- syncope or syncope, that are suggestive of an underlying cardiac arrhythmia; or
- Patient is undergoing investigation for the detection of atrial fibrillation following cryptogenic stroke; or
- Patient is planned for AF ablative procedure or has already undergone an AF ablative procedure.
- Patient is able to understand the nature of the study and able to provide written informed consent.
- Patient is willing and able to perform all follow-up visits at the investigational site.
- Patient is willing and able to use the CardioMessenger and accepts the BIOTRONIK Home Monitoring concept.
Who cannot join
- Patient is implanted with an ICD or pacemaker.
- Patient is pregnant or breast-feeding.
- Patient is less than 18 years old.
- Patient's life-expectancy is less than 12 months.
- Patient is participating in another interventional clinical investigation.
Trial locations and contacts
27 sites in 6 countries.
27 sites in 6 countries
Germany11 sites
RHÖN-KLINIKUM Campus Bad Neustadt
Bad Neustadt an der Saale
Herz- und Diabeteszentrum NRW
Bad Oeynhausen
Städtisches Klinikum Dresden-Friedrichstadt
Dresden
Universitätsklinik an der Technischen Universität Dresden
Dresden
SRH Wald-Klinikum Gera GmbH
Gera
Universitätsklinikum Gießen und Marburg GmbH (UKGM)
Giessen
Ernst-Moritz-Arndt-Universität Greifswald
Greifswald
Klinikum St. Georg gGmbH
Leipzig
Klinikum Leverkusen Service GmbH
Leverkusen
St.-Marien-Hospital GmbH
Lünen
Johannes Wesling Klinikum Minden
Minden
Australia6 sites
GenesisCare Wesley
Auchenflower
GenesisCare Bundaberg
Bundaberg
GenesisCare Doncaster
Doncaster East
Canberra Heart Rhythm Clinic
Garran
Prince of Wales Hospital
Randwick
Princess Alexandra Hospital
Woolloongabba
Austria3 sites
Kepler Universitätsklinikum
Linz
Allgemeines Krankenhaus der Stadt Wien (AKH)
Vienna
Klinikum Wels-Grieskirchen
Wels
Spain3 sites
Hospital del Bierzo
León
Complejo Hospitalario de Ourense
Ourense
Hospital Universitario Marques de Valdecilla
Santander
Switzerland3 sites
CHUV - Centre Hospitalier Universitaire Vaudoise
Lausanne
Fondazione Cardiocentro Ticino
Lugano
Kantonsspital St. Gallen
Sankt Gallen
About this study
Official title: BIO|MASTER.BIOMONITOR III
This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III and BIOMONITOR IIIm that are discovered or remain even after risk analysis, risk mitigation and successful conformity assessment. Furthermore, this study will also provide additional data as required by regulatory authorities outside of the CE-region.
- Conditions
- Tachyarrhythmia, Atrial Fibrillation (AF), Syncope, Cryptogenic Stroke
- Being tested
- BIOMONITOR III and BIOMONITOR IIIm
- Medical subject headings
- Tachycardia, Atrial Fibrillation, Syncope, Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BIOMONITOR III and BIOMONITOR IIImDevice
- Insertion of BIOMONITOR III or BIOMONITOR IIIm
- three scheduled in-office follow-ups
- 48-hour Holter ECG
| Study group | Role | What they receive |
|---|---|---|
| all patients | Other | Not described Receives: Device: BIOMONITOR III and BIOMONITOR IIIm |
What is being measured
The primary outcome is the main question the study is designed to answer.
SADE-free Rate Until the 3-month Follow-up
SADE-free rate related to BIOMONITOR III and BIOMONITOR IIIm including incision and insertion tool set until 3-month follow-up
Measured: 3 months
Secondary outcomes (4)
R-wave Amplitude
The secondary endpoint 1 evaluates the R-wave amplitude at the 1st follow-up and at 3-month follow-up by measuring both, the lowest and the highest amplitude value via the programmer.
Measured: 10 days to 4 weeks after insertion; 3-months
Noise Burden
The secondary endpoint 2 evaluates the noise burden at the 1st follow-up and at 3-month follow-up by retrieving the percentage of noise via the programmer.
Measured: 10 days to 4 weeks after insertion; 3-months
Assessment of P-wave Visibility
The secondary endpoint 3 evaluates the P-wave visibility at 1st, 3- and 12-month follow-up. The investigator will evaluate whether P-waves can be recognized in the stored sECGs showing sinus rhythm. The number of heart cycles and observed P-waves which can undoubtly be identified in ECGs will be assessed by the investigator.
Measured: 10 days to 4 weeks after insertion; 3-months
SADE-free Rate Until the 12-month Follow-up
The secondary endpoint 4 is the SADE-free rate related to the BIOMONITOR III and BIOMONITOR IIIm 12 months after insertion.
Measured: 12-months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jul 2019
- Study start17 Oct 2019
- Primary completion30 Jun 2021
- Study completion6 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for TachyarrhythmiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 167 participants (actual)
Sponsor and investigators
- Lead sponsor
- Biotronik SE & Co. KG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Thomas Deneke, Prof. Dr., Principal investigator, RHÖN-KLINIKUM Campus Bad Neustadt, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04025710
- Sponsor's protocol ID
- BA109
- Status last verified
- Nov 2022
- First submitted
- 17 Jul 2019
- Last updated
- 27 Nov 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BIO|MASTER.BIOMONITOR III
- ClinicalTrials.gov ID
- NCT04025710
- Acronym / sponsor ID
- BA109
- Conditions
- Tachyarrhythmia, Atrial Fibrillation (AF), Syncope, Cryptogenic Stroke
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 167 participants (actual)
- Lead sponsor
- Biotronik SE & Co. KGIndustry (pharma, biotech, devices)
- Study start
- 17 Oct 2019 (actual)
- Primary completion
- 30 Jun 2021 (actual)
- Study completion
- 6 Apr 2022 (actual)
- First posted
- 19 Jul 2019 (actual)
- Results
- Posted 11 Jan 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III and BIOMONITOR IIIm that are discovered or remain even after risk analysis, risk mitigation and successful conformity assessment. Furthermore, this study will also provide additional data as required by regulatory authorities outside of the CE-region.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| all patients | Other | Device: BIOMONITOR III and BIOMONITOR IIIm |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patient is at high risk of developing a clinically important cardiac arrhythmia; or
- Patient is undergoing investigation for symptoms such as palpitations, pre- syncope or syncope, that are suggestive of an underlying cardiac arrhythmia; or
- Patient is undergoing investigation for the detection of atrial fibrillation following cryptogenic stroke; or
- Patient is planned for AF ablative procedure or has already undergone an AF ablative procedure.
- Patient is able to understand the nature of the study and able to provide written informed consent.
Key exclusion criteria (5 listed)
- Patient is implanted with an ICD or pacemaker.
- Patient is pregnant or breast-feeding.
- Patient is less than 18 years old.
- Patient's life-expectancy is less than 12 months.
- Patient is participating in another interventional clinical investigation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BIOMONITOR III and BIOMONITOR IIIm* Insertion of BIOMONITOR III or BIOMONITOR IIIm * three scheduled in-office follow-ups * 48-hour Holter ECG | Device | all patients |
Primary outcome
SADE-free Rate Until the 3-month Follow-up
Time frame: 3 months
SADE-free rate related to BIOMONITOR III and BIOMONITOR IIIm including incision and insertion tool set until 3-month follow-up
4 secondary outcomes
R-wave Amplitude
Time frame: 10 days to 4 weeks after insertion; 3-months
Noise Burden
Time frame: 10 days to 4 weeks after insertion; 3-months
Assessment of P-wave Visibility
Time frame: 10 days to 4 weeks after insertion; 3-months
SADE-free Rate Until the 12-month Follow-up
Time frame: 12-months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Nov 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Tachyarrhythmia
Recruiting
SPIKE FLOW Endocardial Lead Safety and Performance Study
Acute Myocardial Infarction (AMI), Asystole
Recruiting
Optimal Settings for Anti Tachycardia Pacing (ATP) on ICD
Heart Disease, Implantable Cardioverter Defibrillator (ICD)
Enrolling by invitationObservational study
Lead Evaluation for Defibrillation and Reliability Post Approval Study
Tachyarrhythmia
RecruitingObservational study
BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs
Tachyarrhythmia, Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas Deneke, Prof. Dr. principal investigator
RHÖN-KLINIKUM Campus Bad Neustadt, Germany
27 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing BIOMONITOR III and BIOMONITOR IIIm in people with Tachyarrhythmia and Atrial Fibrillation (AF), run by Biotronik SE & Co. KG at 27 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 27 sites in Germany, Australia, Austria, Spain, Switzerland and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 11 Jan 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SADE-free Rate Until the 3-month Follow-up (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Nov 2024; AzTrials last refreshed its copy on 26 Oct 2026.